Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension

NCT03282266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-10-03

No results posted yet for this study

Summary

The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of PADN for the treatment of PAH.

Conditions

Interventions

PROCEDURE

PADN

PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.

PROCEDURE

Sham operation

The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.

Sponsors & Collaborators

  • Pulnovo Medical (Wuxi) Co., Ltd.

    collaborator INDUSTRY
  • Guangdong Provincial People's Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER
  • Tianjin Medical University General Hospital

    collaborator OTHER
  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER
  • Beijing Anzhen Hospital

    collaborator OTHER
  • Shenyang Northern Hospital

    collaborator OTHER
  • The Second Affiliated Hospital of Chongqing Medical University

    collaborator OTHER
  • Tongji Hospital

    collaborator OTHER
  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Hang Zhang, MD · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2021-06-22
Completion
2021-12-22

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282266 on ClinicalTrials.gov